此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Belantamab Mafodotin、硼替佐米和地塞米松与 Daratumumab、硼替佐米和地塞米松在复发/难治性多发性骨髓瘤参与者中的疗效和安全性评价 (DREAMM 7)

2026年10月29日 更新者:GlaxoSmithKline

DREAMM 7:一项多中心、开放标签、随机 III 期研究,旨在评估 Belantamab Mafodotin、硼替佐米和地塞米松 (B-Vd) 联合疗法与 Daratumumab、硼替佐米和地塞米松联合疗法 (D-Vd) 相比的疗效和安全性) 在患有复发/难治性多发性骨髓瘤的参与者中

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

研究概览

研究类型

介入性

注册 (实际的)

494

阶段

  • 第三阶段

扩展访问

得到正式认可的 出售给公众。 查看扩展访问记录。

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100191
        • GSK Investigational Site
      • Beijing、中国、100020
        • GSK Investigational Site
      • Changchun、中国、130012
        • GSK Investigational Site
      • Guangzhou、中国、510060
        • GSK Investigational Site
      • Guangzhou、中国、510515
        • GSK Investigational Site
      • Hangzhou、中国、310003
        • GSK Investigational Site
      • Jinan、中国、250012
        • GSK Investigational Site
      • Nanjing、中国、210008
        • GSK Investigational Site
      • Shenyang、中国、110001
        • GSK Investigational Site
      • Suzhou、中国、215006
        • GSK Investigational Site
      • Tianjin、中国、300020
        • GSK Investigational Site
      • Zhengzhou、中国、450052
        • GSK Investigational Site
      • Jerusalem、以色列、91120
        • GSK Investigational Site
      • Kfar Saba、以色列、44281
        • GSK Investigational Site
      • Ramat Gan、以色列、52621
        • GSK Investigational Site
      • Tel Aviv、以色列、64239
        • GSK Investigational Site
      • Moscow、俄罗斯、125284
        • GSK Investigational Site
      • Nizhny Novgorod、俄罗斯、603126
        • GSK Investigational Site
      • Novosibirsk、俄罗斯、630087
        • GSK Investigational Site
      • Saint Petersburg、俄罗斯、191024
        • GSK Investigational Site
      • Saint Petersburg、俄罗斯、197 089
        • GSK Investigational Site
      • Samara、俄罗斯、443021
        • GSK Investigational Site
      • Saratov、俄罗斯、410028
        • GSK Investigational Site
      • Ufa、俄罗斯、450083
        • GSK Investigational Site
    • Alberta
      • Edmonton、Alberta、加拿大、T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London、Ontario、加拿大、N6A 5W9
        • GSK Investigational Site
      • Toronto、Ontario、加拿大、M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal、Quebec、加拿大、H4J 1C5
        • GSK Investigational Site
      • Joinville、巴西、89201-260
        • GSK Investigational Site
      • Natal、巴西、59075-740
        • GSK Investigational Site
      • Rio de Janeiro、巴西、22775001
        • GSK Investigational Site
      • São Paulo、巴西、04537-080
        • GSK Investigational Site
      • São Paulo、巴西、05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、巴西、90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis、Santa Catarina、巴西、88020-210
        • GSK Investigational Site
      • Athens、希腊、11528
        • GSK Investigational Site
      • Thessaloniki、希腊、54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli、East Macedonia and Thrace、希腊、681 00
        • GSK Investigational Site
      • Cologne、德国、50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm、Baden-Wurttemberg、德国、89081
        • GSK Investigational Site
    • Bavaria
      • München、Bavaria、德国、81377
        • GSK Investigational Site
      • Würzburg、Bavaria、德国、97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf、North Rhine-Westphalia、德国、40225
        • GSK Investigational Site
    • Thuringia
      • Jena、Thuringia、德国、07747
        • GSK Investigational Site
      • Bergamo、意大利、24127
        • GSK Investigational Site
      • Bologna、意大利、40138
        • GSK Investigational Site
      • Brescia、意大利、25123
        • GSK Investigational Site
      • Catania、意大利、95123
        • GSK Investigational Site
      • Meldola FC、意大利、47014
        • GSK Investigational Site
      • Milan、意大利、20133
        • GSK Investigational Site
      • Ravenna、意大利、48121
        • GSK Investigational Site
      • Roma、意大利、00168
        • GSK Investigational Site
      • Siena、意大利、53100
        • GSK Investigational Site
      • Torino、意大利、10126
        • GSK Investigational Site
      • Brno、捷克语、625 00
        • GSK Investigational Site
      • Hradec Králové、捷克语、500 05
        • GSK Investigational Site
      • Ostrava、捷克语、708 52
        • GSK Investigational Site
      • Prague、捷克语、128 08
        • GSK Investigational Site
      • Christchurch、新西兰、8011
        • GSK Investigational Site
      • Dunedin、新西兰、9054
        • GSK Investigational Site
      • Takapuna Auckland、新西兰、1309
        • GSK Investigational Site
      • Wellington、新西兰、6021
        • GSK Investigational Site
      • Aichi、日本、467-8602
        • GSK Investigational Site
      • Aichi、日本、441-8570
        • GSK Investigational Site
      • Aomori、日本、030-8553
        • GSK Investigational Site
      • Ehime、日本、790-8524
        • GSK Investigational Site
      • Fukuoka、日本、806-8501
        • GSK Investigational Site
      • Fukuoka、日本、807-8555
        • GSK Investigational Site
      • Fukuoka、日本、810-8563
        • GSK Investigational Site
      • Fukuoka、日本、815-8555
        • GSK Investigational Site
      • Gifu、日本、503-8502
        • GSK Investigational Site
      • Gunma、日本、377-0280
        • GSK Investigational Site
      • Hyōgo、日本、670-8540
        • GSK Investigational Site
      • Kanagawa、日本、247-8533
        • GSK Investigational Site
      • Kanagawa、日本、221-0855
        • GSK Investigational Site
      • Kochi、日本、781-8555
        • GSK Investigational Site
      • Nagano、日本、392-8510
        • GSK Investigational Site
      • Okayama、日本、701-1192
        • GSK Investigational Site
      • Osaka、日本、545-8586
        • GSK Investigational Site
      • Osaka、日本、530-0012
        • GSK Investigational Site
      • Shizuoka、日本、411-8777
        • GSK Investigational Site
      • Roeselare、比利时、8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette、Brussels Capital、比利时、1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert、Brussels Capital、比利时、1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent、Oost-Vlaanderen、比利时、9000
        • GSK Investigational Site
      • Amiens、法国、80054
        • GSK Investigational Site
      • Caen、法国、14033
        • GSK Investigational Site
      • Nice、法国、06200
        • GSK Investigational Site
      • Paris、法国、75651
        • GSK Investigational Site
      • Rennes、法国、35033
        • GSK Investigational Site
      • Chorzów、波兰、41-500
        • GSK Investigational Site
      • Krakow、波兰、30510
        • GSK Investigational Site
      • Lodz、波兰、93-513
        • GSK Investigational Site
      • Lublin、波兰、20-081
        • GSK Investigational Site
      • Lublin、波兰、20-090
        • GSK Investigational Site
      • Nowy Sącz、波兰、33-300
        • GSK Investigational Site
      • Poznan、波兰、60-569
        • GSK Investigational Site
      • Warsaw、波兰、02-781
        • GSK Investigational Site
    • New South Wales
      • Camperdown、New South Wales、澳大利亚、2050
        • GSK Investigational Site
      • Liverpool、New South Wales、澳大利亚、2170
        • GSK Investigational Site
      • Newcastle、New South Wales、澳大利亚、2298
        • GSK Investigational Site
      • St Leonards、New South Wales、澳大利亚、2065
        • GSK Investigational Site
      • Wollongong、New South Wales、澳大利亚、2500
        • GSK Investigational Site
    • Queensland
      • Benowa、Queensland、澳大利亚、4217
        • GSK Investigational Site
      • Herston、Queensland、澳大利亚、4029
        • GSK Investigational Site
    • South Australia
      • Ashford、South Australia、澳大利亚、5037
        • GSK Investigational Site
    • Victoria
      • Box Hill、Victoria、澳大利亚、3128
        • GSK Investigational Site
      • Heidelberg、Victoria、澳大利亚、3084
        • GSK Investigational Site
      • Melbourne、Victoria、澳大利亚、3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch、Western Australia、澳大利亚、6150
        • GSK Investigational Site
      • Nedlands、Western Australia、澳大利亚、6009
        • GSK Investigational Site
    • Arizona
      • Yuma、Arizona、美国、85364
        • GSK Investigational Site
    • Kansas
      • Mission、Kansas、美国、66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver、North Carolina、美国、80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash、Ohio、美国、45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler、Texas、美国、75702
        • GSK Investigational Site
    • Virginia
      • Roanoke、Virginia、美国、24014
        • GSK Investigational Site
      • Bournemouth、英国、BH7 7DW
        • GSK Investigational Site
      • Cardiff、英国、CF14 4XW
        • GSK Investigational Site
      • Dundee、英国、DD1 9SY
        • GSK Investigational Site
      • Leicester、英国、LE1 5WW
        • GSK Investigational Site
      • London、英国、W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent、英国、ST4 6QG
        • GSK Investigational Site
      • Sutton、英国、SM2 5PT
        • GSK Investigational Site
      • Groningen、荷兰、9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht、South Holland、荷兰、3318 AT
        • GSK Investigational Site
      • Barcelona、西班牙、08035
        • GSK Investigational Site
      • Barcelona、西班牙、08916
        • GSK Investigational Site
      • Cáceres、西班牙、10003
        • GSK Investigational Site
      • Gijón、西班牙、33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega、西班牙、08908
        • GSK Investigational Site
      • MOstoles Madrid、西班牙、28933
        • GSK Investigational Site
      • Madrid、西班牙、28007
        • GSK Investigational Site
      • Madrid、西班牙、31008
        • GSK Investigational Site
      • Murcia、西班牙、30008
        • GSK Investigational Site
      • PamplonaNavarra、西班牙、31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr、西班牙、28223
        • GSK Investigational Site
      • Salamanca、西班牙、37007
        • GSK Investigational Site
      • Pusan、韩国、49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do、韩国、13620
        • GSK Investigational Site
      • Seoul、韩国、06351
        • GSK Investigational Site
      • Seoul、韩国、06591
        • GSK Investigational Site
      • Ulsan、韩国、44033
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Belantamab mafodotin 和硼替佐米加地塞米松(A 组)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

有源比较器:Daratumumab 和硼替佐米加地塞米松(B 组)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free Survival (PFS)
大体时间:Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

次要结果测量

结果测量
措施说明
大体时间
眼科检查中出现异常眼部发现的参与者人数
大体时间:长达 73 个月
长达 73 个月
Complete Response Rate (CRR)
大体时间:Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
大体时间:Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
大体时间:Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
大体时间:Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
大体时间:Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
大体时间:Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
大体时间:Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
大体时间:Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
大体时间:Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
大体时间:Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
大体时间:Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
大体时间:Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
大体时间:Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
大体时间:Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
大体时间:Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
大体时间:Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
大体时间:Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
大体时间:Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
大体时间:Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
大体时间:Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
大体时间:Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:GSK Clinical Trials、GlaxoSmithKline

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年5月7日

初级完成 (实际的)

2023年10月2日

研究完成 (估计的)

2029年10月8日

研究注册日期

首次提交

2020年1月27日

首先提交符合 QC 标准的

2020年1月27日

首次发布 (实际的)

2020年1月29日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年10月29日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅